AGIOS PHARMACEUTICALS, INC. License and Services Revenue (Deprecated 2018-01-31)
AGIOS PHARMACEUTICALS, INC. (AGIO) reported License and Services Revenue (Deprecated 2018-01-31) of $7.34 million for the 3-month period ending 2018-03-31, per its 10-Q filed 2018-05-04.
Discontinued › Income Statement › Other Income
us-gaap:LicenseAndServicesRevenue · last filed 2018-05-04
- AGIOS PHARMACEUTICALS, INC. license and services revenue (deprecated 2018-01-31) for the quarter ending 2018-03-31 was $7.34M, a 30.10% decline year-over-year.
- AGIOS PHARMACEUTICALS, INC. license and services revenue (deprecated 2018-01-31) for the quarter ending 2017-12-31 was $8.58M, a 62.13% decline year-over-year.
- AGIOS PHARMACEUTICALS, INC. license and services revenue (deprecated 2018-01-31) for the quarter ending 2017-09-30 was $10.64M, a 18.45% increase year-over-year.
- AGIOS PHARMACEUTICALS, INC. license and services revenue (deprecated 2018-01-31) for the quarter ending 2017-03-31 was $10.51M.
- AGIOS PHARMACEUTICALS, INC. license and services revenue (deprecated 2018-01-31) for fiscal 2017 was $41.07M, a 41.23% decline from fiscal 2016.
- AGIOS PHARMACEUTICALS, INC. license and services revenue (deprecated 2018-01-31) for fiscal 2016 was $69.89M, a 18.22% increase from fiscal 2015.
- AGIOS PHARMACEUTICALS, INC. license and services revenue (deprecated 2018-01-31) for fiscal 2015 was $59.12M.
- AGIOS PHARMACEUTICALS, INC. license and services revenue (deprecated 2018-01-31) for fiscal 2013 was $25.55M, a 1.90% increase from fiscal 2012.
| Period end | License and Services Revenue (Deprecated 2018-01-31) 3 month | License and Services Revenue (Deprecated 2018-01-31) 6 month | License and Services Revenue (Deprecated 2018-01-31) 9 month | License and Services Revenue (Deprecated 2018-01-31) 12 month |
|---|---|---|---|---|
| 2018-03-31 | $7.34M 10-Q · filed 2018-05-04 | $15.92M derived: sum of 2 quarters · filed 2018-05-04 | $26.57M derived: sum of 3 quarters · filed 2018-05-04 | |
| 2017-12-31 | $8.58M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-14 | $19.22M derived: sum of 2 quarters · filed 2018-02-14 | $41.07M 10-K · filed 2018-02-14 | |
| 2017-09-30 | $10.64M 10-Q · filed 2017-11-01 | $32.50M 10-Q · filed 2017-11-01 | ||
| 2017-03-31 | $10.51M 10-Q · filed 2018-05-04 | $33.16M derived: sum of 2 quarters · filed 2018-05-04 | $42.14M derived: sum of 3 quarters · filed 2018-05-04 | |
| 2016-12-31 | $22.65M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-14 | $31.63M derived: sum of 2 quarters · filed 2018-02-14 | $69.89M 10-K · filed 2018-02-14 | |
| 2016-09-30 | $8.98M 10-Q · filed 2017-11-01 | $47.24M 10-Q · filed 2017-11-01 | ||
| 2015-12-31 | $59.12M 10-K · filed 2018-02-14 | |||
| 2013-12-31 | $25.55M 10-K · filed 2014-03-18 | |||
| 2012-12-31 | $25.07M 10-K · filed 2014-03-18 | |||
| 2011-12-31 | $21.80M 10-K · filed 2014-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |